What we really need is data, based on which we can make informed decisions. All that we have at the moment is DCGI approval of the vaccines. But for the programme to make a decision, I would expect that they do a risk-benefit analysis, said Gagandeep Kang, professor of microbiology at CMC Vellore.from Industry-Economic Times
Read The Rest:economictimes...
